Your browser doesn't support javascript.
loading
Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database.
Yekedüz, Emre; Ertürk, Ismail; Tural, Deniz; Karadurmus, Nuri; Karakaya, Serdar; Hizal, Mutlu; Arikan, Rukiye; Arslan, Çagatay; Taban, Hakan; Küçükarda, Ahmet; Öztas, Nihan Sentürk; Sever, Özlem Nuray; Uçar, Gökhan; Can, Orçun; Sendur, Mehmet Ali; Demirci, Umut; Kiliçkap, Saadettin; Çiçin, Irfan; Öksüzoglu, Berna; Özgüroglu, Mustafa; Ürün, Yüksel.
  • Yekedüz E; Department of Medical Oncology, Faculty of Medicine, Ankara University, Ankara, 06590, Turkey.
  • Ertürk I; Cancer Research Institute, Ankara University, Ankara, 06590, Turkey.
  • Tural D; Department of Medical Oncology, Gülhane Education & Research Hospital, University of Health Sciences, Ankara, 06010, Turkey.
  • Karadurmus N; Department of Medical Oncology, Bakirköy Dr. Sadi Konuk Training & Research Hospital, University of Health Sciences, Istanbul, 34147, Turkey.
  • Karakaya S; Department of Medical Oncology, Gülhane Education & Research Hospital, University of Health Sciences, Ankara, 06010, Turkey.
  • Hizal M; Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Education & Research Hospital, University of Health Sciences, Ankara, 06200, Turkey.
  • Arikan R; Department of Medical Oncology, Ankara City Hospital, University of Health Sciences, Ankara, 06800, Turkey.
  • Arslan Ç; Department of Medical Oncology, Marmara University, Istanbul, 34899, Turkey.
  • Taban H; Department of Medical Oncology, Izmir University of Economics, Izmir, 35575, Turkey.
  • Küçükarda A; Department of Medical Oncology, Hacettepe University, Ankara, 06230, Turkey.
  • Öztas NS; Department of Medical Oncology, Trakya University, Edirne, 22020, Turkey.
  • Sever ÖN; Division of Medical Oncology, Istanbul University-Cerrahpasa, Istanbul, 34098, Turkey.
  • Uçar G; Department of Medical Oncology, Gaziantep University, Gaziantep, 27070, Turkey.
  • Can O; Department of Medical Oncology, Ankara City Hospital, University of Health Sciences, Ankara, 06800, Turkey.
  • Sendur MA; Department of Medical Oncology, Prof. Dr. Cemil Tasçioglu City Hospital, University of Health Sciences, Istanbul, 34384, Turkey.
  • Demirci U; Department of Medical Oncology, Ankara Yildirim Beyazit University, Ankara, 06800, Turkey.
  • Kiliçkap S; Department of Medical Oncology, Üsküdar University, Memorial Ankara Hospital, Ankara, 06520, Turkey.
  • Çiçin I; Department of Medical Oncology, Hacettepe University, Ankara, 06230, Turkey.
  • Öksüzoglu B; Department of Medical Oncology, Istinye University, Istanbul, 34010, Turkey.
  • Özgüroglu M; Department of Medical Oncology, Trakya University, Edirne, 22020, Turkey.
  • Ürün Y; Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Education & Research Hospital, University of Health Sciences, Ankara, 06200, Turkey.
Future Oncol ; 17(35): 4861-4869, 2021 12.
Article en En | MEDLINE | ID: mdl-34726480
Lay abstract Nivolumab is an immune checkpoint inhibitor (ICI) that blocks the communication between T cells and cancer cells and instead activates T cells to fight against cancer. Metastatic renal cell carcinoma (mRCC) is one of the most susceptible tumors to ICIs. The Checkmate 025 trial showed the efficacy of nivolumab in patients with previously treated mRCC. In this real-world study, 173 patients with mRCC were treated with nivolumab in the second line and beyond. Nivolumab was effective in the real-world setting without additional safety concerns.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Terapia Molecular Dirigida / Nivolumab / Inhibidores de Puntos de Control Inmunológico / Neoplasias Renales Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Aged / Female / Humans / Male / Middle aged País como asunto: Asia Idioma: En Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Terapia Molecular Dirigida / Nivolumab / Inhibidores de Puntos de Control Inmunológico / Neoplasias Renales Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Aged / Female / Humans / Male / Middle aged País como asunto: Asia Idioma: En Año: 2021 Tipo del documento: Article